Does burst-suppression achieve seizure control in refractory status epilepticus?

Area of Science:

• Neuroscience
• Anesthesiology
• Critical Care Medicine

Background:

• Anesthetic drug administration principles include seizure suppression and electroencephalography burst suppression (BS).
• Previous studies yielded conflicting results on BS effects due to varied anesthetic agents, patient selection (e.g., continuous electroencephalography monitoring), and inclusion of anoxic encephalopathy.
• This study focuses on refractory status epilepticus (RSE) patients to clarify the impact of midazolam-induced BS.

Purpose of the Study:

• To analyze the effect of midazolam-induced electroencephalography burst suppression (BS) on outcomes in patients with refractory status epilepticus (RSE).
• To evaluate the association between BS and breakthrough seizures, withdrawal seizures, intra-hospital complications, functional outcomes, and mortality.

Main Methods:

• Prospective database of patients diagnosed with status epilepticus via continuous electroencephalography (cEEG).
• Multivariate Poisson regression models, guided by a directed acyclic graph (DAG), were used to estimate the effect of midazolam-induced BS.
• Analysis included breakthrough seizure, withdrawal seizure, intra-hospital complications, 3-month functional outcome, and mortality.

Main Results:

• 51 RSE patients (non-anoxic encephalopathy) were analyzed; 51% achieved BS.
• The BS group had significantly fewer breakthrough seizures (Incidence Risk Ratio [IRR] = 0.30; 95% CI = 0.13–0.74).
• No significant association was found between BS and increased withdrawal seizures, intra-hospital complications, mortality, or functional outcomes.

Conclusions:

• Electroencephalography burst suppression (BS) induced by midazolam is safe for RSE patients.
• BS is associated with a reduced incidence of breakthrough seizures.
• BS does not increase the rate of intra-hospital complications or negatively affect long-term functional outcomes.